Insider Selling: Stoke Therapeutics (NASDAQ:STOK) CFO Sells 2,382 Shares of Stock

19 Mar 2026, 18:42 by Amy Steele · The Cerbat Gem

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) CFO Thomas Leggett sold 2,382 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $74,651.88. Following the transaction, the chief financial officer directly owned 10,172 shares of the company’s stock, valued at $318,790.48. This trade represents a 18.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Thomas Leggett also recently made the following trade(s):

On Tuesday, March 17th, Thomas Leggett sold 2,196 shares of Stoke Therapeutics stock. The stock was sold at an average price of $33.01, for a total value of $72,489.96.

Stoke Therapeutics Price Performance

NASDAQ:STOK traded up $2.17 during midday trading on Thursday, reaching $33.19. 853,428 shares of the company traded hands, compared to its average volume of 754,489. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $40.22. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 49.54 and a beta of 1.07. The company has a fifty day moving average price of $32.61 and a 200 day moving average price of $29.90.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Thursday. Canaccord Genuity Group boosted their target price on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Guggenheim started coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They issued a “buy” rating and a $60.00 target price for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Finally, Wolfe Research assumed coverage on Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $39.83.

Check Out Our Latest Report on Stoke Therapeutics

Key Headlines Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

Positive Sentiment: Multiple analysts raised or reiterated bullish ratings and price targets this week (BTIG reaffirmed “buy” with a $39 target; Wedbush lifted its target to $38; Needham raised its target toward $40 and Chardan keeps a $35 target) — these actions increase buy-side interest and provide technical/supportive buying. Read More.
Positive Sentiment: Pipeline story: coverage highlighting STK‑001’s potential to restore developmental deficits in Dravet syndrome (beyond seizure control) supports upside for long-term clinical value if trials continue to show benefit. Read More.
Neutral Sentiment: Company granted inducement stock options to new hires — helps recruiting but adds potential future dilution; not an immediate earnings impact. Read More.
Negative Sentiment: Quarterly results missed expectations: EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.3M expected — the earnings/revenue shortfall is the clearest near-term driver of prior downward pressure and investor concern about near-term commercialization/visibility. Read More.
Negative Sentiment: Insider sale disclosed — Director Arthur A. Levin sold 605 shares (~$22k) in mid‑March; small in dollar terms but sometimes interpreted as a mild negative signal by short‑term traders. Read More.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. bought a new stake in shares of Stoke Therapeutics during the 3rd quarter worth about $1,062,000. Marshall Wace LLP increased its stake in shares of Stoke Therapeutics by 7.9% during the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after acquiring an additional 168,771 shares during the period. Penserra Capital Management LLC acquired a new position in shares of Stoke Therapeutics during the third quarter valued at approximately $3,539,000. Franklin Resources Inc. raised its holdings in Stoke Therapeutics by 264.8% during the second quarter. Franklin Resources Inc. now owns 81,395 shares of the company’s stock worth $924,000 after purchasing an additional 59,081 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Stoke Therapeutics by 7.4% during the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after purchasing an additional 217,616 shares in the last quarter.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.